Selskabets formål er fabrikation og handel, herunder fabrikation af og handel med kemiske, farmaceutiske, kosmetiske og tilsvarende produkter
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 565.3 mio. | 7.3 mio. | 216.7 mio. | 78.2 mio. | 52 | |
CVR: 55541817
Secondary names: SmithKline Beecham Consumer Healthcare ApS, Sterling Health ApS, Sterwin ApS
Compared to 405 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Haleon Denmark ApS demonstrates a stable financial health with consistent revenue growth over the past few years. Revenue increased from 437.96 million DKK in 2020 to 565.33 million DKK in 2024, while profit has remained relatively stable, peaking at 8.54 million DKK in 2022 before slightly declining to 7.30 million DKK in 2024. The company’s equity has shown a positive trajectory, rising from 63.28 million DKK in 2022 to 78.16 million DKK in 2024, indicating a strengthening financial position. However, the notable drop in profit margins raises concerns about operational efficiency. Overall, Haleon Denmark ApS is positioned well within the pharmaceutical wholesale industry, benefiting from steady demand for medicinal and healthcare products.
AI-generated summary
Companies in the same industry and area
CVR 27394019
CVR 16406899
CVR 42541877
CVR 45267024
CVR 43401548
companydata.dk